Altwegg, Romain

Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease

Beaugerie, L., Svrcek, M., Seksik, P., Bouvier, A., Simon, T., Allez, M., Brixi, H., Gornet, J., Altwegg, R., Beau, P., et al. (2013) · Gastroenterology

Inflammatory Bowel DiseaseColorectal Cancer Screening and Detection

Cited by 363

Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes

Faillie, J., Yin, H., Yu, O. H. Y., Herrero, A., Altwegg, R., Renoux, C., & Azoulay, L. (2022) · Clinical Pharmacology & Therapeutics

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 67

Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID multicentre cohort study

Caron, B., Peyrin-Biroulet, L., Pariente, B., Bouhnik, Y., Seksik, P., Bouguen, G., Caillo, L., Laharie, D., Carbonnel, F., Altwegg, R., et al. (2019) · Journal of Crohn's and Colitis

Liver Diseases and ImmunityInflammatory Bowel Disease

Cited by 60

Safety of anti-TNF treatment in liver transplant recipients: a systematic review and meta-analysis

Westerouen van Meeteren, M. J., Hayee, B., Inderson, A., van der Meulen, A. E., Altwegg, R., van Hoek, B., Pageaux, G. P., Stijnen, T., Stein, D., & Maljaars, P. W. J. (2017) · Journal of Crohn's and Colitis

Organ Transplantation Techniques and OutcomesInflammatory Bowel Disease

Cited by 39

Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: a nationwide case series

Altwegg, R., Combes, R., Laharie, D., De Ledinghen, V., Radenne, S., Conti, F., Chazouilleres, O., Duvoux, C., Dumortier, J., Leroy, V., et al. (2018) · Digestive and Liver Disease

Inflammatory Bowel DiseaseLiver Diseases and Immunity

Cited by 34